Stay updated with breaking news from Stephen Betschel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
– Patient perspectives revealed frequent treatment delays, suboptimal clinical outcomes and substantial anxiety associated with injectable on-demand treatments, including those who received...
– Late-breaking phase 3 data for KONFIDENT trial on Sunday, February 25, 2024 – ...
– Late-breaking phase 3 data for KONFIDENT trial on Sunday, February 25, 2024 –CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--$KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule pro...
– Sebetralstat pharmacokinetic and pharmacodynamic data support globalization of the KONFIDENT phase 3 clinical trial and use in short-term prophylaxis – – Real-world patient data... | June 12, 2023
– Phase 1 data provide rationale for sebetralstat as short-term prophylaxis for medical and dental procedures - – Patient survey data demonstrate treatment burden associated with... | May 8, 2023